|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.26 USD | -0.90% |
|
+1.17% | +6.63% |
| Mar. 08 | NRSInsights Reports 3.5% Rise in Same-Store Sales in February | MT |
| Mar. 06 | Transcript : IDT Corporation, Q2 2024 Earnings Call, Mar 06, 2024 |
BERLIN, Nov 23 (Reuters) - Germany's IDT Biologika plans to start a phase II trial of its experimental COVID-19 vaccine by the end of the year and hopes to be able to apply for approval in 2021, its Chief Executive said on Monday.
"If all clinical tests are successful, we could apply for an accelerated approval at the end of 2021," said Juergen Betzing at a news conference in Dessau. (Reporting by Thomas Seythal and Kirsti Knolle)
| 1st Jan change | Capi. | |
|---|---|---|
| +6.63% | 929M | |
| +9.26% | 197B | |
| +4.36% | 166B | |
| -0.37% | 115B | |
| -1.68% | 92.72B | |
| +18.72% | 73.08B | |
| -0.57% | 57.5B | |
| -5.07% | 50.83B | |
| -14.46% | 39.78B | |
| -33.53% | 38.22B |
IDT CORPORATION 
